TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18635690

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 17191050

Group type: EXPERIMENTAL
Intervention: Emollient containing oat extracts
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (no emollient)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both groups (emollient and control)
Number of subjects: 173
Study: 15056989

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 1 hour of physical exercise twice a week for 5 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 33
Study: 15523434

Group type: EXPERIMENTAL
Intervention: Oil-based oral spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water-based oral spray (placebo)
Number of subjects: 20
Study: 10028949

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 8747042

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (0.5 mg/day s.c.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose leuprolide acetate depot (1.88 mg s.c.)
Number of subjects: 100
Study: 2167804

Group type: EXPERIMENTAL
Intervention: 4 hours of oxygen withdrawal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Routine oxygen therapy
Number of subjects: 8
Study: 6268283

Group type: EXPERIMENTAL
Intervention: Intermediate course of irradiation (ICI) of 5000 rads in 25 fractions, 200 rads each, in 5 weeks
Number of subjects: 343

Group type: COMPARATOR
Intervention: Short course of irradiation (SCI) of 4200 rads in 15 fractions, 280 rads each, in 3 weeks
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Both ICI and SCI
Number of subjects: 343
Study: 31533737

Group type: EXPERIMENTAL
Intervention: Minneapolis Staple Foods Ordinance (policy requiring food stores to stock minimum quantities and varieties of healthy foods)
Number of subjects: 3039
Study: 29851806

Group type: EXPERIMENTAL
Intervention: Cross tape applied at 45° to the right of the flexor digitorum superficialis muscle fibers
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cross tape applied at 45° to the left of the flexor digitorum superficialis muscle fibers
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Modified O‐ring test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Maximal pinch strength using pinch gauge
Number of subjects: 39
Study: 26728048

Group type: EXPERIMENTAL
Intervention: Navigated PLF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional PLF
Number of subjects: 40
Study: 25240708

Group type: EXPERIMENTAL
Intervention: Listening to a 10‐min audiotape of infant crying
Number of subjects: 111

Group type: COMPARATOR
Intervention: Listening to a 10‐min audiotape of infant cooing
Number of subjects: 111
Study: 21868743

Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy, aerobic physical activity, tadalafil administration
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group A (PSV <25 cm/s)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Patients with AED
Number of subjects: 120
Study: 20200926

Group type: EXPERIMENTAL
Intervention: ALN 5 mg/day
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: ALN 10 mg/day
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099
Study: 17698837

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) as a primary endpoint
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: A priori hypothesis relevant to palliation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Clinically meaningful differences in QoL or symptom scores
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Analysis of differences between mean or median scores
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Definition of palliative response
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Overall quality of studies
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Improvement in methodology and reporting over time
Number of subjects: 112
Study: 16230122

Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corticosteroid (deflazacort, 30 mg daily) plus tamsulosin
Number of subjects: 60
Study: 12460529

Group type: EXPERIMENTAL
Intervention: Website condition
Number of subjects: 30
Study: 10482144

Group type: EXPERIMENTAL
Intervention: 16-mm NIR stent
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 32-mm NIR stent
Number of subjects: 280

Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 280
Study: 7756099

Group type: EXPERIMENTAL
Intervention: Intravenous frusemide: 40 mg bolus then 40 mg h‐1 for 3 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Captopril: two 12.5 mg oral doses separated by 2 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined dosing: first captopril dose preceded the frusemide bolus by 30 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Frusemide alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Frusemide with captopril
Number of subjects: 8
Study: 31592692

Group type: EXPERIMENTAL
Intervention: Epigenetic age acceleration measures using DNA methylation from blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrinsic epigenetic age acceleration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extrinsic epigenetic age acceleration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PhenoAge Acceleration
Number of subjects: 0
Study: 28089163

Group type: COMPARATOR
Intervention: Volar locking plates
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fragment-specific fixation
Number of subjects: 50
Study: 26786987

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy with Venturi mask for first 12 hours of admission
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study: 23502992

Group type: EXPERIMENTAL
Intervention: Home-based disease management
Number of subjects: 161

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 161
Study: 21482635

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention of 225 min/week
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group maintaining usual activity levels
Number of subjects: 320
Study: 19690345

Group type: EXPERIMENTAL
Intervention: Dietary intervention plus quadriceps strengthening exercises
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Dietary intervention alone
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening exercises alone
Number of subjects: 389

Group type: COMPARATOR
Intervention: Advice leaflet only (control group)
Number of subjects: 389
Study: 16970537

Group type: EXPERIMENTAL
Intervention: Gargling with tea catechin extract solution (200 microg/mL catechins, 60% epigallocatechin gallate), performed three times daily for 3 months.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Gargling without tea catechin extracts (control group), performed three times daily for 3 months.
Number of subjects: 124
Study: 10999673

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 729

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study: 9076204

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry in normal subjects
Number of subjects: 78

Group type: COMPARATOR
Intervention: Scanning laser polarimetry in patients with OHT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry in normal subjects (inferior retina)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Scanning laser polarimetry in patients with OHT (inferior retina)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry in normal subjects (superior retina)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Scanning laser polarimetry in patients with OHT (superior retina)
Number of subjects: 78
Study: 8363079

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clonidine (37.5 micrograms)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clonidine (75 and 150 micrograms)
Number of subjects: 54
Study: 3752350

Group type: EXPERIMENTAL
Intervention: Lenox Hill Derotation Brace (LHB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No brace condition
Number of subjects: 10
Study: 31164059

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for six months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 31
Study: 28738266

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 26552175

Group type: EXPERIMENTAL
Intervention: OMT low dose (1.89 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: OMT medium dose (3.78 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: OMT high dose (7.56 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SB203580 (p38MAPK blocking agent, 1 x 10(‐5) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (serum free DMEM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Model group (20 μg x L(‐1) TGF‐β1)
Number of subjects: 6
Study: 23863086

Group type: EXPERIMENTAL
Intervention: Kuan-Sin-Yin (KSY) decoction
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (KSY diluted 16 times)
Number of subjects: 57
Study: 22042952

Group type: EXPERIMENTAL
Intervention: 6 months of androgen suppression therapy (AST)
Number of subjects: 761

Group type: COMPARATOR
Intervention: 3 or 4 months of androgen suppression therapy (AST)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: AST duration of 6 months
Number of subjects: 761

Group type: COMPARATOR
Intervention: AST duration of 3 or 4 months
Number of subjects: 761
Study: 18648865

Group type: EXPERIMENTAL
Intervention: Gow-Gates mandibular block with device
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gow-Gates mandibular block without device (control group)
Number of subjects: 90
Study: 16543470

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy
Number of subjects: 0
Study: 14529705

Group type: EXPERIMENTAL
Intervention: Targeting tasks (females with CAH)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Targeting tasks (males with CAH)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Mental rotations tasks (females with CAH)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Mental rotations tasks (males with CAH)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Targeting tasks (unaffected females)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Targeting tasks (unaffected males)
Number of subjects: 128
Study: 10905240

Group type: EXPERIMENTAL
Intervention: Active treatment (omeprazole 20 mg, clarithromycin 250 mg, and tinidazole 500 mg, each twice daily for 7 days)
Number of subjects: 2324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2324

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2324

Group type: EXPERIMENTAL
Intervention: Active treatment and placebo
Number of subjects: 2324
Study: 8730248

Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg at 07.30 h (early evening)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg at 22.00 h (bedtime)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 1417177

Group type: EXPERIMENTAL
Intervention: r‐hGH (0.1 mg/kg/day or 0.2 mg/kg/day) + insulin (1 mU/kg/minute)
Number of subjects: 28

Group type: COMPARATOR
Intervention: insulin (1 mU/kg/minute)
Number of subjects: 28
Study: 3903581

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 100
Study: 31923070

Group type: EXPERIMENTAL
Intervention: Opioid use disorder treatment
Number of subjects: 260
Study: 29661095

Group type: EXPERIMENTAL
Intervention: Early sensory relearning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional relearning
Number of subjects: 20
Study: 28429967

Group type: EXPERIMENTAL
Intervention: Knee arthroscopic surgery combined with a 3-month exercise program
Number of subjects: 150

Group type: COMPARATOR
Intervention: 3-month exercise program alone (nonsurgery group)
Number of subjects: 150
Study: 25786714

Group type: EXPERIMENTAL
Intervention: Topical clobetasol 0.05% applied at night
Number of subjects: 60

Group type: COMPARATOR
Intervention: Systemic mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 60
Study: 23743482

Group type: EXPERIMENTAL
Intervention: 12-week LSC videos
Number of subjects: 238

Group type: COMPARATOR
Intervention: 12-week HIV prevention messages (text messages)
Number of subjects: 238
Study: 20472399

Group type: EXPERIMENTAL
Intervention: LPD 7/7 (low protein diet providing 0.8 g/kg per day, 7 days a week)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: LPD 6/7 (low protein diet providing 0.8 g/kg per day, 6 days a week)
Number of subjects: 52
Study: 18432491

Group type: EXPERIMENTAL
Intervention: LOVIT (outpatient low-vision programme)
Number of subjects: 176

Group type: COMPARATOR
Intervention: BRC (inpatient blind rehabilitation centres)
Number of subjects: 176
Study: 15979226

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (C‐SE) with prior etching using 40% phosphoric acid (K‐etchant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clearfil SE Bond (C‐SE) without prior etching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (C‐SE) with prior etching on dentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (C‐SE) with prior etching
Number of subjects: 0
Study: 15231567

Group type: EXPERIMENTAL
Intervention: Brief anthracycline-based chemotherapy plus high-dose extended irradiation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Classical Hodgkin lymphoma without mediastinal involvement (cHL without MI)
Number of subjects: 500
Study: 11300386

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, bolus of 0.05 ml/kg, lockout interval of 10 min, total dose limit of three bolus doses per hour.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Continuous epidural infusion (EPI) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, continuous infusion of 0.1 ml kg(‐1) h(‐1) and a minimal extra bolus dose of 0.2 ml with the same lockout interval.
Number of subjects: 54
Study: 9129064

Group type: EXPERIMENTAL
Intervention: zalcitabine (0.03 mg/kg/day) in combination with zidovudine (720 mg/m2/day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: zidovudine monotherapy
Number of subjects: 250
Study: 8169480

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 71

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 71

Group type: COMPARATOR
Intervention: Transbursal endoscopic technique
Number of subjects: 71

Group type: COMPARATOR
Intervention: Extrabursal endoscopic technique
Number of subjects: 71
Study: 3203716

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg oral dose in the fasted state
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefixime 400 mg oral dose with a standard breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg oral dose in the fed state
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg oral dose in both states
Number of subjects: 20
Study: 31743987

Group type: EXPERIMENTAL
Intervention: Corticosteroid (COR) injection
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Prolotherapy (PRO) injection
Number of subjects: 129
Study: 30513882

Group type: EXPERIMENTAL
Intervention: Satisfying rehearsal condition
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Dissatisfying rehearsal condition
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Neutral rehearsal condition
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 128
Study: 26694927

Group type: EXPERIMENTAL
Intervention: Warm humidified CO2 insufflation
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (no warm humidified CO2 insufflation)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: End-of-operation wound edge temperature
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Age (10-year increase)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cancer diagnosis
Number of subjects: 158
Study: 25186739

Group type: EXPERIMENTAL
Intervention: 2 years of community music training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 year of community music training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater amounts of instrumental music training beyond 1 year
Number of subjects: 0
Study: 21958377

Group type: EXPERIMENTAL
Intervention: Supervised Tai Chi
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 152
Study: 21254641

Group type: EXPERIMENTAL
Intervention: Standard antibacterial treatment plus immunotropic drug (lavomax) 1.25 g
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard antibacterial treatment
Number of subjects: 40
Study: 18294367

Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme (1-hour sessions, 3 times per week for 8 months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme
Number of subjects: 33
Study: 15860436

Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamins E and C, beta-carotene, and reduced total, polyunsaturated, and saturated fat intake
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Vitamin E intake
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) and polyunsaturated fatty acid (PUFA) intake
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Arachidonic acid intake
Number of subjects: 202
Study: 12639206

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (50 mg/d)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 11095459

Group type: EXPERIMENTAL
Intervention: Drug therapy (fenfluramine, 60 mg/day) coupled with an energy-restricted diet (−2930 kJ/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weight loss protocol (fenfluramine + diet)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-insulin individuals
Number of subjects: 42
Study: 8842601

Group type: EXPERIMENTAL
Intervention: Brief intervention (touchscreen computer-assisted assessment, goal setting, problem-solving counseling)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 206
Study: 1502965

Group type: EXPERIMENTAL
Intervention: Knowledge maps
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Scripted cooperation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Text format
Number of subjects: 111

Group type: COMPARATOR
Intervention: Individual processing
Number of subjects: 111
Study: 6331149

Group type: EXPERIMENTAL
Intervention: Fiber supplemented breakfast (F)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional breakfast (C)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fiber supplemented lunch (F)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional lunch (C)
Number of subjects: 6
Study: 30994773

Group type: EXPERIMENTAL
Intervention: GLUMA Universal-self-etch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GLUMA Universal-selective etching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GLUMA Universal-etch-and-rinse
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All-Bond Universal-self-etch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All-Bond Universal-selective etching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All-Bond Universal-etch-and-rinse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single Bond2-etch-and-rinse (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study: 29490294

Group type: EXPERIMENTAL
Intervention: Furosemide (60-120 mg/day, intravenously) for 1 week
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no furosemide or other diuretics)
Number of subjects: 26
Study: 27957487

Group type: EXPERIMENTAL
Intervention: 1.5 mA A-tDCS for 15 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study: 25268730

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (364 mg daily for 42 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (identical capsule daily for 42 days)
Number of subjects: 48
Study: 22977989

Group type: EXPERIMENTAL
Intervention: Wipe product
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spray product
Number of subjects: 0
Study: 21077563

Group type: EXPERIMENTAL
Intervention: Reliable automation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unreliable automation (miss)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unreliable automation (false alarm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual performance
Number of subjects: 12
Study: 18689370

Group type: EXPERIMENTAL
Intervention: Bread fortified with 138 µg folic acid and 9.6 µg vitamin B-12 daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: Unfortified bread
Number of subjects: 142
Study: 16199244

Group type: EXPERIMENTAL
Intervention: Muraglitazar 2.5 mg
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Muraglitazar 5 mg
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Muraglitazar 5 mg (open-label cohort)
Number of subjects: 340